FGFR3

By Type:	Pan (43) Selective (6)

Cat. No.	Product Name	Effect	Purity

HY-10981

Lenvatinib	Inhibitor	99.75%
Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.

HY-50904

Nintedanib	Inhibitor	99.94%
Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/Flt-1/2/3, FGFR1/2/3 and PDGFRα/β with IC₅₀s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-18708

Erdafitinib	Inhibitor	99.66%
Erdafitinib (JNJ-42756493) is a potent and orally available FGFR family inhibitor; inhibits FGFR1/2/3/4 with IC₅₀s of 1.2, 2.5, 3.0 and 5.7 nM, respectively.

HY-13311

Infigratinib	Inhibitor	99.72%
Infigratinib (BGJ-398; NVP-BGJ398) is a potent inhibitor of the FGFR family with IC₅₀s of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.

HY-109099

Pemigatinib	Inhibitor	99.84%
Pemigatinib (INCB054828) is an orally active, selective FGFR inhibitor with IC₅₀s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma.

HY-164459

AZ8010	Inhibitor
AZ8010 (AZ12908010) is a potent FGFR1-3 inhibitor. AZ8010 has anti-proliferative activity and can be used for the research of cancer.

HY-159503A

Segigratinib hydrochloride	Inhibitor
Segigratinib hydrochloride (3D185) is a potent inhibitor of FGFR1/2/3 and CSF-1R; The IC₅₀ values for FGFR1, FGFR2, FGFR3 and CSF-1R are 0.5, 1.3, 3.6 and 3.8 nM, respectively. Segigratinib hydrochloride has antitumor activity.

HY-100818

Futibatinib	Inhibitor	99.65%
Futibatinib (TAS-120) is an orally bioavailable, highly selective, and irreversible FGFR inhibitor, with IC₅₀s of 3.9, 1.3, 1.6, and 8.3 nM for FGFR 1-4, respectively. Futibatinib inhibits mutant and wild-type FGFR2 with similar IC₅₀s (wild-type FGFR2=0.9 nM; V5651=1-3 nM; N550H=3.6 nM; E566G=2.4 nM).

HY-13330

Fexagratinib	Inhibitor	99.85%
Fexagratinib (AZD4547; ADSK091) is a potent inhibitor of the FGFR family with IC₅₀s of 0.2 nM, 2.5 nM, 1.8 nM, and 165 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.

HY-11106

Nintedanib esylate	Inhibitor	99.95%
Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor for VEGFR1/Flt-1/2/3, FGFR1/2/3 and PDGFRα/β with IC₅₀s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-10981A

Lenvatinib mesylate	Inhibitor	99.86%
Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.

HY-50905

Dovitinib	Inhibitor	99.88%
Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC₅₀s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/Flt-1/VEGFR2/KDR/Flk-1/VEGFR3/Flt-4 and PDGFRα/PDGFRβ, respectively. Dovitinib has potent antitumor activity.

HY-12823

BLU9931	Inhibitor	99.97%
BLU9931 is a potent, highly selective, and irreversible fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC₅₀ of 3 nM and a K_d of 6 nM. BLU9931 has significant antitumor activity.

HY-101568

Roblitinib	Inhibitor	99.74%
Roblitinib (FGF-401) is an orally active and highly selective FGFR4 inhibitor with an IC₅₀ of 1.9 nM. Roblitinib has antitumor activity.

HY-100019

Rogaratinib	Inhibitor	99.86%
Rogaratinib (BAY1163877) is a potent and selective fibroblast growth factor receptor (FGFR) inhibitor. Rogaratinib inhibits FGFRs with IC50s of 11.2 nM (FGFR1), <1 nM (FGFR2), 18.5 nM (FGFR3), 127 nM (VEGFR3/Flt-4/FLT4), 201 nM (FGFR4), respectively.

HY-13304

LY2874455	Inhibitor	98.03%
LY2874455 is a pan-FGFR inhibitor with IC₅₀s of 2.8, 2.6, 6.4, 6 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively.

HY-13034

Gandotinib	Inhibitor	99.82%
Gandotinib (LY2784544) is a potent JAK2 inhibitor with IC₅₀ of 3 nM. Gandotinib (LY2784544) also inhibits FLT3, FLT4, FGFR2, TYK2, and TRKB with IC₅₀ of 4, 25, 32, 44, and 95 nM.

HY-10032

PF 477736	Inhibitor	99.21%
PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of Chk1, with a K_i of 0.49 nM, it is also a Chk2 inhibitor, with a K_i of 47 nM. PF 477736 shows <100-fold selectivity for Chk1 over VEGFR2/KDR/Flk-1, Fms, Yes, Aurora-A, FGFR3, Flt3, and Ret (IC₅₀=8 (K_i), 10, 14, 23, 23, 25, and 39 nM, respectively). PF 477736 can enhance Gemcitabine antitumor activity in vitro and in vivo.

HY-P99384

Vofatamab	Inhibitor
Vofatamab (B-701) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC).

HY-13311A

Infigratinib phosphate	Inhibitor	99.74%
Infigratinib phosphate (BGJ-398 phosphate; NVP-BGJ398 phosphate) is a potent inhibitor of the FGFR family with IC₅₀ of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.

Name
Email *

	Sorry, but the email address you supplied was invalid.

FGFR3 Related Products (56)